Beta
Trial Radar KI
Die klinische Studie NCT07466511 für Idiopathische Skoliose ist noch nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht

Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis 100

Noch nicht rekrutierend
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07466511 ist eine interventionsstudie zur Untersuchung von Idiopathische Skoliose und hat den Status noch nicht rekrutierend. Der Start ist für 1. Januar 2027 geplant, bis 100 Teilnehmer aufgenommen werden. Durchgeführt von Second Affiliated Hospital of Wenzhou Medical University wird der Abschluss für 31. Dezember 2030 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 12. März 2026 aktualisiert.
Kurzbeschreibung
Researchers hypothesized that Bifidobacterium breve Supplement could reduce the progression rate of idiopathic scoliosis in children and potentially prevent the occurrence of new cases of scoliosis.
Ausführliche Beschreibung
Idiopathic scoliosis (IS) is a common pediatric disorder characterized by a spinal curvature exceeding 10 degrees that develops in the absence of obvious congenital or physiological defects. IS is highly prevalent during adolescence, afflicting 3-4% of children worldwide, yet the underlying causes remain poorly understood. Recent studies have indicated that children with idiopathic scoliosis have a disrupted gut micr...Mehr anzeigen
Offizieller Titel

Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis: A Prospective, Single-Blind, Randomized Controlled Trial

Erkrankungen
Idiopathische Skoliose
Weitere Studien-IDs
  • SAHoWMU-CR2026-08-103
NCT-Nummer
Studienbeginn (tatsächlich)
2027-01-01
Zuletzt aktualisiert
2026-03-12
Studienende (vorauss.)
2030-12-31
Geplante Rekrutierung
100
Studientyp
Interventionsstudie
PHASE
Nicht zutreffend
Status
Noch nicht rekrutierend
Primäres Ziel
Behandlung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Einfach verblindet
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
ExperimentellBifidobacterium breve Supplementation plus Lifestyle Education
Participants in this arm will receive oral Bifidobacterium breve supplementation at a dose of 4.5 × 10\^6 CFU daily for 6 months, together with a one-time standardized lifestyle education session at baseline. The education program will include guidance on healthy diet, appropriate physical activity, and avoidance of unnecessary antibiotic use. Adherence to probiotic supplementation will be reinforced by regular telep...Mehr anzeigen
Bifidobacterium breve
Oral Bifidobacterium breve supplementation, 4.5 × 10\^6 CFU daily for 6 months
Lifestyle Education
A standardized education session delivered at baseline on diet optimization, appropriate exercise, and avoidance of unnecessary antibiotic use.
Aktives VergleichspräparatLifestyle Education Only
Participants in this arm will receive the same standardized lifestyle education session and study materials as the experimental group, but no probiotic supplementation will be provided.
Lifestyle Education
A standardized education session delivered at baseline on diet optimization, appropriate exercise, and avoidance of unnecessary antibiotic use.
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Change in Major Cobb Angle
Major curve magnitude will be measured on standing full-spine radiographs using the standard Cobb method.
Baseline and every 6 months up to 24 months
Change in Angle of Trunk Rotation (ATR)
Trunk asymmetry will be assessed using a scoliometer to measure angle of trunk rotation.
Baseline and every 6 months up to 24 months
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Scoliosis Research Society-22 (SRS-22) Questionnaire Score
Health-related quality of life will be assessed using the SRS-22 questionnaire, including pain, self-image, function, mental health, and treatment satisfaction.
Baseline and every 6 months up to 24 months
Gut Microbiota Composition
Gut microbial composition in stool samples will be assessed using metagenomic sequencing or polymerase chain reaction methods.
Baseline and Month 6
Gastrointestinal Symptoms
Gastrointestinal symptoms and bowel movement frequency will be assessed through structured interview.
Baseline and Month 6
Serum Bile Acid Levels
Serum bile acid concentrations will be measured using blood samples collected from participants.
Baseline and Month 6
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Kind
Mindestalter
6 Years
Zugelassene Geschlechter
Alle
  • Age 6 to 15 years

Diagnosed with idiopathic scoliosis based on clinical evaluation and radiographic examination at the first clinic visit

Skeletally immature, defined as Risser sign 0 to 3

Major Cobb angle < 40 degrees at baseline

Written informed consent provided by the participant or legal guardian

Able and willing to comply with study procedures

  • Plans to relocate within the next 24 months

Use of antibiotics, probiotics, hormones, immunosuppressants, or other nutritional supplements known to affect gut microbiota within the past 3 months or during the study period without investigator approval

Known allergy, sensitivity, or intolerance to the investigational product or its ingredients

Current or prior significant gastrointestinal disease requiring medication, or history of gastrointestinal surgery

Severe gastrointestinal symptoms such as persistent heartburn or indigestion

Musculoskeletal, neurodevelopmental, syndromic, or other conditions that may account for the spinal deformity

History of spine surgery or major spinal injury

Spinal tumor or malignant disease involving the spine

Leg length discrepancy > 20 mm

Severe chronic diseases that could interfere with study participation or outcome assessment, including but not limited to diabetes, narcolepsy, or poorly controlled asthma

Severe obesity, defined as BMI z-score ≥ 3

Second Affiliated Hospital of Wenzhou Medical University logoSecond Affiliated Hospital of Wenzhou Medical University
Verantwortliche Partei
Xiangyang Wang, Hauptprüfer, M.D., Chief physician, Doctorial superviso, Second Affiliated Hospital of Wenzhou Medical University
Zentrale Studienkontakte
Kontakt: Xiangyang Wang, 13506663458, [email protected]
1 Studienstandorte in 1 Ländern

Zhejiang

The Second Affiliated Hospital of Wenzhou Medical University, Zhejiang, Zhejiang 325000, Wenzhou, Zhejiang, 325600, China
Xiangyang Wang, Kontakt, 13506663458, [email protected]